What is NDC 55150-381?

55150-381 is the product NDC for Pemetrexed, Pemetrexed disodium hemipentahydrate 100 mg/4mL injection, powder, lyophilized, for solution, listed with the FDA by Eugia US LLC. It has 1 package NDC, shown above in 10- and 11-digit form.

What is the active ingredient?

Pemetrexed disodium hemipentahydrate.

Eugia US LLC, NDC labeler code 55150. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Pemetrexed?

57 other product NDCs are listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Pemetrexed NDC 55150-381 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)55150-381Labeler and product segments. Claims need a package NDC.

Product NDC at billing width55150-0381Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
55150-381-01	5515003810155150038101	1 VIAL in 1 CARTON (55150-381-01) / 4 mL in 1 VIALMarketed from May 25, 2022

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Pemetrexed
Generic name (nonproprietary): pemetrexed
Active ingredients: Pemetrexed disodium hemipentahydrate — 100 mg/4mL
Dosage form: Injection, Powder, Lyophilized, For solution
Route: Intravenous
Labeler: Eugia US LLCNDC labeler code 55150
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 214632
Marketing start: May 25, 2022
Listing expires: Dec 31, 2026
Other FDA classes: Folic Acid Metabolism Inhibitors (Mechanism)
Identifiers: Product ID 55150-381_d9465d8d-67cb-4650-8c84-a9293d45ac92SPL ID d9465d8d-67cb-4650-8c84-a9293d45ac92SPL set ID 737ead51-f73c-414f-b68f-d3affc27a225RxCUI 1728072, 1728077, 2601728UNII F4GSH45R4CUPC 0355150382019, 0355150383016, 0355150381012
Pharmacologic class: Folate Analog Metabolic Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N455150038101 followed by a unit qualifier and the quantity

Package 55150-0381-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jul 27, 2023.

Indications (excerpt from the label)

Pemetrexed for injection is a folate analog metabolic inhibitor indicated: • in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations. ( 1.1 ) • in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous NSCLC. ( 1.1 ) • as a single agent for the maintenance treatment of patients with locally advanced or metastatic, non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. ( 1.1 ) • as a single agent for the treatment of patients…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 55150-381

What is NDC 55150-381?: 55150-381 is the product NDC for Pemetrexed, Pemetrexed disodium hemipentahydrate 100 mg/4mL injection, powder, lyophilized, for solution, listed with the FDA by Eugia US LLC. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Pemetrexed.
What is the active ingredient?: Pemetrexed disodium hemipentahydrate.
Who is the labeler?: Eugia US LLC, NDC labeler code 55150. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Pemetrexed?: 57 other product NDCs are listed under this name. See all Pemetrexed NDCs.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other finished products listed under the same name: strengths, forms and labelers.

Other Pemetrexed NDCs
Product	Strength	Form · route	Labeler	Product NDC	Package NDCs (11-digit)
Pemetrexedpemetrexed disodium	Pemetrexed disodium heptahydrate 100 mg/4mL	Injection, Powder, Lyophilized, For solutionIntravenous	Somerset Therapeutics LLC	70069-834	70069-0834-01
Pemetrexedpemetrexed disodium	Pemetrexed disodium heptahydrate 500 mg/20mL	Injection, Powder, Lyophilized, For solutionIntravenous	Somerset Therapeutics LLC	70069-835	70069-0835-01
Pemetrexedpemetrexed disodium	Pemetrexed disodium hemipentahydrate 100 mg/4.2mL	Injection, Powder, Lyophilized, For solutionIntravenous	Sagent Pharmaceuticals	25021-260	25021-0260-10
Pemetrexedpemetrexed disodium	Pemetrexed disodium hemipentahydrate 500 mg/20mL	Injection, Powder, Lyophilized, For solutionIntravenous	Sagent Pharmaceuticals	25021-261	25021-0261-50
Pemetrexedpemetrexed disodium	Pemetrexed disodium hemipentahydrate 100 mg/10mL	Injection, Powder, Lyophilized, For solutionIntravenous	NorthStar RxLLC	72603-325	72603-0325-01
Pemetrexedpemetrexed disodium	Pemetrexed disodium hemipentahydrate 500 mg/50mL	Injection, Powder, Lyophilized, For solutionIntravenous	NorthStar RxLLC	72603-425	72603-0425-01
Pemetrexed	Pemetrexed disodium hemipentahydrate 100 mg/1	Injection, Powder, For solutionIntravenous	Solco Healthcare US, LLC	43547-632	43547-0632-01
Pemetrexedpemetrexed disodium	Pemetrexed disodium hemipentahydrate 100 mg/4mL	Injection, Powder, Lyophilized, For solutionIntravenous	Camber Pharmaceuticals, Inc.	31722-336	31722-0336-31
Pemetrexedpemetrexed disodium	Pemetrexed disodium hemipentahydrate 500 mg/20mL	Injection, Powder, Lyophilized, For solutionIntravenous	Camber Pharmaceuticals, Inc.	31722-337	31722-0337-31
Pemetrexedpemetrexed disodium	Pemetrexed disodium hemipentahydrate 100 mg/10mL	InjectionIntravenous	Shilpa Medicare Limited	63759-3048	63759-3048-01

All 58 Pemetrexed NDCs

Other NDCs under ANDA 214632

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 214632
Product	Strength	Form · route	Labeler	Product NDC
Pemetrexed	Pemetrexed disodium hemipentahydrate 500 mg/20mL	Injection, Powder, Lyophilized, For solutionIntravenous	Eugia US LLC	55150-382
Pemetrexed	Pemetrexed disodium hemipentahydrate 1000 mg/40mL	Injection, Powder, Lyophilized, For solutionIntravenous	Eugia US LLC	55150-383
Pemetrexed	Pemetrexed disodium hemipentahydrate 100 mg/4mL	Injection, Powder, Lyophilized, For solutionIntravenous	BluePoint Laboratories	68001-535
Pemetrexed	Pemetrexed disodium hemipentahydrate 500 mg/20mL	Injection, Powder, Lyophilized, For solutionIntravenous	BluePoint Laboratories	68001-536